Shanghai Pharmaceutical Group, namely Shanghai Pharmaceutical Group Co., Ltd., can also be referred to as Shanghai Pharmaceutical for short. The major shareholder is Shanghai Pharmaceutical (Group) Co., Ltd., with a shareholding ratio of 65,438+09.3732%. It is a large pharmaceutical industry group listed in Shanghai and Hong Kong, and the actual controller is Shanghai SASAC.
Since its establishment, Shanghai Pharmaceutical has been adhering to the concept of openness, cooperation and win-win, constantly carrying out high-level innovation cooperation with leading universities, medical institutions and scientific research institutes in China, covering the fields of early cultivation of innovative drugs, construction of clinical research platform, innovation of traditional Chinese medicine, secondary development, etc., and has been committed to establishing an innovative R&D platform closely connected with Industry-University-Research to continuously stimulate innovation vitality.
In addition, the industrial manufacturing scope of Shanghai Pharmaceuticals also covers chemical biomedicine, modern Chinese medicine health care products, medical devices and other fields, focusing on seven therapeutic fields, such as anti-tumor, cardiovascular and cerebrovascular diseases, mental nerves, anti-infection, autoimmunity, digestion and metabolism, and respiratory system. It has established pharmaceutical production bases in 65,438+02 provinces and cities in China and overseas, and produces about 700 different medicines each year, covering more than 20 different dosage forms.
By 2022, the sales of 48 products of Shanghai Pharmaceutical have exceeded 1 100 million yuan, and many of them have passed the quality certification of WHO, FDA and EU, and successfully entered overseas markets. The company also developed 2/kloc-0 rare diseases, covering 34 different rare diseases.
If you need to know more about Shanghai Pharmaceutical Group, I suggest you go to the enterprise to find out-check the enterprise for free.